1140.HK stock closes HKD 0.18 on 10 Mar 2026: PB 0.19 frames value debate

1140.HK stock closed at HKD 0.18 on 10 Mar 2026 after a quiet session on the HKSE in Hong Kong. The price fell 2.19% on the day to finish near the 50-day average of HKD 0.19, with volume of 272000.00 shares. HK.AI Capital Limited (1140.HK) shows a low price-to-book of 0.19 and a trailing PE of 18.00, putting valuation at odds with steady cash on the balance sheet. Investors focused on AI-related opportunities should weigh the firm’s asset strength against thin daily liquidity.

1140.HK stock price action and liquidity

Today 1140.HK stock opened at HKD 0.18 and traded between HKD 0.17 and HKD 0.18. The intraday move produced a change of -0.00 in absolute terms and -2.19% on a previous close of HKD 0.18. Volume was light at 272000.00 versus an average volume of 4698526.00, signalling limited market participation and higher intraday volatility for small trades.

Company profile and business mix for HK.AI Capital Limited (1140.HK)

HK.AI Capital Limited (1140.HK) is listed on the HKSE and operates in financial services and asset management from Central, Hong Kong. The company invests across medical, finance, TMT and health sectors and reports 11657280502.00 shares outstanding. CEO Bingya Qiao leads a team of about 200.00 full time employees. The business mix—with investments in growth sectors—aligns with an AI-stocks strategy that looks for exposure to technology themes through an asset manager wrapper.

Valuation and key financial metrics including Meyka grade

1140.HK stock trades at PE 18.00 and PB 0.19, with cash per share of 0.40 and book value per share of 0.96. Operating cash flow per share is 0.02, and free cash flow per share is 0.02, supporting a strong current ratio of 6.75. These metrics show a conservative balance sheet and low leverage (debt-to-equity 0.07).

Meyka AI rates 1140.HK with a score out of 100: the model gives a 63.35 /100, Grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These inputs favour balance sheet strength but flag modest earnings growth relative to peers.

Technical setup and market signals for 1140.HK stock

Technically, 1140.HK shows neutral momentum. RSI is 45.05 and ADX is 19.04, indicating no clear trend. Bollinger middle band sits at HKD 0.19, with upper HKD 0.21 and lower HKD 0.17. The money flow index is low at 9.54, suggesting short-term oversold conditions. Traders should note on‑balance volume is negative and average daily liquidity is limited, which magnifies slippage risk for larger orders.

Forecasts, targets and analyst outlook for 1140.HK forecast

Meyka AI’s forecast model projects near-term and multi‑period targets for 1140.HK: monthly HKD 0.19, quarterly HKD 0.22, and yearly HKD 0.28. At the current HKD 0.18, the yearly forecast implies an upside of 55.19% and the quarterly target implies 22.91% upside. Forecasts are model-based projections and not guarantees. Market consensus coverage is sparse; investors should combine model outputs with company updates and sector performance.

Risks and opportunities in an AI-stocks strategy for 1140.HK stock

Opportunity: 1140.HK stock offers a low PB and significant cash per share, providing a margin of safety if management monetises holdings. The company’s focus on TMT and health could capture AI-driven growth in portfolio companies.

Risk: Limited liquidity (avg volume 4698526.00 versus low daily trades) and long receivables cycle increase operational exposure. A narrow analyst coverage and a mixed rating profile raise execution risk if markets reprice asset managers.

Final Thoughts

Key takeaways: 1140.HK stock closed at HKD 0.18 on 10 Mar 2026 on the HKSE in Hong Kong, trading below the 50-day average but above the 200-day average, reflecting a mixed short-term picture. The balance sheet is a strength: cash per share 0.40 and PB 0.19 point to tangible asset support. Meyka AI’s forecast model projects HKD 0.28 for a one‑year horizon, implying an upside of 55.19% from the current price of HKD 0.18; monthly and quarterly projections are HKD 0.19 and HKD 0.22 respectively. The proprietary Meyka grade is 63.35 /100 (B, HOLD), which balances conservative fundamentals against modest growth momentum. For investors using an AI-stocks approach, 1140.HK can serve as a value-oriented exposure to TMT and health sector upside, but position sizes should consider limited liquidity and execution risk. Forecasts are model-based projections and not guarantees; verify with company reports and market updates before trading. For related market comparisons see Investing.com research and peer compilers source and source. Meyka AI provides this as an AI-powered market analysis platform tool to support further research.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.